



10745 Westside Way, Suite 200, Alpharetta, GA USA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

ASX Announcement

Visioneering Technologies, Inc. receives patent in China for Myopia Progression Control Designs

Atlanta, Georgia, USA 23 August 2017: Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, is pleased to announce that China has allowed the Company's patent protection of VTI's optical designs when used for Myopia Progression Control.

China joins Singapore, Taiwan, and Australia which have also allowed the patent, protecting Visioneering's innovative designs when used in Myopia Progression Control until the year 2036. Further territories are also pending for this patent.

In addition, Singapore has recently allowed the Company's patent that will broadly protect the use of VTI's multi-focal designs in any vision care application, until the year 2036. This patent is also pending in additional jurisdictions.

Asia is a very large potential market for VTI's innovative designs, with near 90 per cent of the youth in some Asian countries suffering from progressive myopia and in need of a solution.

Visioneering's CEO, Dr Stephen Snowdy said, "Successful protection of our innovations through intellectual property is an important accelerant in our growth and creation of value. These patent allowances layer on top of the other patents in our extensive portfolio of intellectual properties, and have expiries that provide very long protection in key geographies."

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About VTI:

Visioneering Technologies, Inc. (VTI) is a US-based medical device company primarily engaged in the design, manufacture, sale and distribution of a revolutionary new contact lens: the NaturalVue™ Multifocal (MF) contact lens. The characteristics of the NaturalVue MF contact lens allow it to be used in two of the largest eye-care markets globally: adults with presbyopia (age-related difficulty in seeing close objects) and children with myopia (near-sightedness, or difficulty seeing distant objects).



10745 Westside Way, Suite 200, Alpharetta, GA USA 30009

Tel: +1 (844) 884 5367

Email: info@vtivision.com

www.vtvision.com

www.vtvisioninvestors.com (for investors)

The NaturalVue MF contact lens employs VTI's Neurofocus Optics™ technology, which was developed, refined and tested over many years. NaturalVue lenses were cleared by the FDA in late 2014 for the correction of refractive errors and VTI commenced a pilot US market launch of NaturalVue MF contact lenses from 2015 that gave way to a broader US launch in 2016 and 2017. VTI sells and plans additional contact lens products.

Foreign ownership restrictions:

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

MKT-VTI-PR27 r0